Clinicopathological analysis of expression of enhancer of zeste homologue 2 in canine mammary carcinoma
Pubblicato online: 05 lug 2022
Pagine: 267 - 272
Ricevuto: 22 dic 2021
Accettato: 20 giu 2022
DOI: https://doi.org/10.2478/jvetres-2022-0033
Parole chiave
© 2022 X. Ren et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Introduction
Enhancer of zeste homologue 2 (EZH2) is the human homologue of
Material and Methods
The expression of EZH2 mRNA and protein in 53 CMC tissue and 8 normal mammary gland tissue samples was measured by quantitative real-time PCR and immunohistochemical staining assay, respectively. The relationship between EZH2 protein expression and clinicopathological features was analysed by χ2 test to further explore the clinical significance of EZH2 in CMCs.
Results
Compared with normal mammary gland tissues, EZH2 mRNA expressions were significantly increased in CMC tissues (P < 0.01). Moreover, normal mammary glands did not express the EZH2 protein but carcinomic glands did, and expression increased in CMCs with high histological grades, especially in histological grade II (P < 0.05). However, EZH2 expression was not related to age, tumour size, or metastasis (P > 0.05). The expression of EZH2 in one type of CMC was not significantly different from the expression in any other type (P > 0.05).
Conclusion
EZH2 is highly expressed in CMCs, indicating that it can be used as a molecular marker for early diagnosis, prognosis, or therapy of CMCs.